BioSpace News Archive

Tevogen Bio Holdings (‘Tevogen Bio’) ( Nasdaq : TVGN ), today announced TVGN 489, its investigational allogeneic SARS-CoV-2 specific Cytotoxic CD8+ T lymphocytes (CTLs) immunotherapy for treatment of COVID-19 in high-risk patients and Long COVID, retains activity against the currently dominant and highly mutated JN.1 strain based on a review of this variant’s protein sequences.

NeoGenomics, Inc. today released its 2023 Environmental, Social, and Governance (ESG) Report highlighting progress toward building a more sustainable, diverse, and equitable company that delivers exceptional customer experience and advanced testing options.

Altimmune, Inc. today announced that it will report its fourth quarter and full year 2023 financial results on Wednesday, March 27, 2024 and will provide a business update.

T2 Biosystems, Inc. today announced plans for the T2Lyme Panel commercial launch and provided recent business updates.

Innovent Biologics, Inc. announces its 2023 annual results and major business updates.

Genece Health today announced that four abstracts demonstrating their deep-learning AI and liquid biopsy technology’s performance were selected for presentation at the upcoming 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.

Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, introduced its SemaCyte® Multiplexing Platform, an expansion to the existing SemaCyte Microcarrier platform to utilize optical barcoding to accelerate screening processes during in vitro drug discovery.

ProVerum Limited announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate the safety and effectiveness of the ProVee System, a ‘stent-like’ expander designed to gently ‘open-up’ the obstructed urethra and alleviate the symptoms caused by BPH.

BioNTech SE reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.